Image

CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients

CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients

Recruiting
18-70 years
All
Phase 1/2
  • Technical (Original)
  • Simplified (AI rewritten)

Powered by AI

Overview

The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.

Eligibility

Inclusion Criteria:

  • Adult (18-70 year old) kidney transplant recipients
  • Patients transitioning from conventional CNI-based immunosuppression to co-stimulatory blockade (belatacept) immunosuppression OR patients who are stable on belatacept immunosuppression at the time of initial CYTOGAM infusion
  • CMV Ig Seronegative Recipient who received a CMV Ig seropositive Donor
  • EBV IgG Positive

Exclusion Criteria:

  • Pregnant people
  • Subjects unwilling to sign consent and complete follow up visits
  • Subjects with IgA immunodeficiency
  • Subjects who are receiving IgG therapy or who have received IgG therapy within two months of study enrollment
  • Patients who do not speak English and would need a translator and translated consent materials in order to obtain informed consent

Study details
    Kidney Transplant; Complications
    CMV

NCT07096453

University of Minnesota

1 November 2025

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.